# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Lt...
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate ...
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly sales of $157.10 million which beat the analyst consensus estimate of ...
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is projected to report quarterly earnings at $0.15 per share on revenue...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Taro Pharmaceutical Indus (NYSE:TARO) from Buy to Neutral and ...
Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate ...
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on re...